Core Viewpoint - Evaxion Biotech A/S plans to change the ratio of its American Depositary Shares (ADSs) from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares, effective around January 13, 2025 [1][5]. Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [6]. - The company focuses on creating personalized vaccines and has a pipeline addressing high unmet medical needs in infectious diseases [6]. ADS Ratio Change Details - The ADS ratio change will automatically exchange every five existing ADSs for one new ADS for holders in the Direct Registration System (DRS) and the Depository Trust Company (DTC) [2][4]. - Registered holders of certificated ADSs must surrender their certificated ADSs to the depositary bank for cancellation to receive the new ADSs [4]. - The change is expected to support liquidity in the company's ADSs, functioning similarly to a one-for-five reverse ADS split [8]. Trading and Market Impact - The trading price of the ADSs is anticipated to increase proportionally due to the ratio change, although no assurance is provided regarding the exact price movement post-change [5]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [9].

Core Viewpoint - Evaxion Biotech A/S is in advanced discussions with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into an equity-type instrument, which is expected to enhance its equity by $3.7 million and improve its capital structure, aiding compliance with Nasdaq listing requirements [1][2][3]. Group 1: Financial Impact - The conversion of €3.5 million is anticipated to increase Evaxion's equity by $3.7 million immediately upon completion [1][2]. - This conversion will significantly reduce the company's overall liabilities, as Evaxion has no debt besides the EIB loan, thereby simplifying its balance sheet and improving financial flexibility and cash flow [2][3]. Group 2: Strategic Importance - The agreement with EIB is a crucial part of Evaxion's strategy to ensure ongoing compliance with Nasdaq listing requirements [1][2]. - The favorable terms being discussed with EIB are expected to strengthen the company's equity and improve its standing in the financial community [3]. Group 3: Timeline and Background - The agreement is expected to be finalized and implemented in the first quarter of 2025 [1][4]. - Evaxion obtained the loan from EIB in 2020, indicating a long-term relationship with the bank [4].

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expansion of the ...

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is ...

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform's unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data allows for continuous refinement of AIImmunology™ thereby broadening the commercial po ...

Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics and machine learning techniques In the ongoing phase 2 trial with personalized cancer vaccine EVX-01, 79% of the AIImmunology™ predicted vaccine targets triggered a tumor-specific immune response, a significant increase from 58% observed in the E ...

The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion's ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology™ from potential partners New data demonstrating the improved performance of EDEN™ will be presented today at the European Conference on Computational Bi ...

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AIImmunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as ...

Precision in Vaccine Target Prediction: These advancements in EvaxMHC's performance are anticipated to further enhance Evaxion's ability to accurately predict vaccine targets Christian Kanstrup, Evaxion's CEO, comments: "Our results demonstrate significant improvements in the prediction of peptide-MHC interactions, particularly for MHC class II molecules, which have historically been difficult to predict accurately. With this advancement on AI-Immunology™ we now have a more reliable and effective tool for d ...

affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospe ...